Maverex Posters at ISPOR Europe 2020

 

ISPOR Europe is one of our favourite fixtures on the Maverex calendar. Although this year will be slightly different and we’re disappointed to not be flying out to Milan, we’re still looking forward to logging on to the virtual conference from the comfort of the Maverex office and our own homes.

This year, ISPOR will be publishing four posters from Maverex relating to this year’s exciting conference theme, ‘Improving Health: Establishing Incentives and Sharing Value’:

  • Impact of HTA Recommendations on the Use of Fixed-Dose Combination (FDC) Triple Therapy for Patients with Chronic Obstructive Pulmonary Disease (COPD)

Together with our partners at Boehringer Ingelheim, we analysed the relationship between HTA recommendations and market penetration of two new FDC triple therapies: glycopyrronium bromide/formoterol fumarate/beclomethasone and umeclidinium/vilanterol/fluticasone furoate. This poster discusses the restrictions imposed on the use of FDC triple therapy and the results of those initiatives in response to overuse of ICS-based regimens.

  • The Clinical and Cost Impact of Adherence to Chronic Obstructive Pulmonary Disease Guidance Recommendations in England

In this study, also developed with our partners at Boehringer Ingelheim, we modelled the clinical and economic impact of adapting current clinical practice in the management of patients with Chronic Obstructive Pulmonary Disease to treatment according to national and international guideline recommendations. By developing a cost-consequence model that uses a treatment-mapping matrix, we concluded that compared to actual prescribing patterns, treatment according to recommendations results in an ~8% annual reduction in expenditure.

  • The Patient Engagement Process in Rare Diseases

The value of patient engagement in assessing new treatments in HTAs is widely recognised. Inspired by our experience developing materials to demonstrate value in treatments for rare disease, we reviewed the different approaches to patient engagement in the HTAs of orphan drugs in four countries (Australia, Canada, England and Scotland). Patient engagement approaches varied substantially. This study illustrates the need to formalise and the approach to patient engagement to ensure equitable access to orphan drugs.

  • A Review of Exceptional Circumstances Marketing Authorisations Granted by the European Medicines Agency

The extreme rarity of certain conditions make it impossible or unethical to collect comprehensive efficacy and safety data for new therapies. In these situations, marketing authorisation under exceptional circumstances (EC) may be a pathway to market approval in Europe. In this study, we reviewed all therapeutic medicines authorised under EC, with a focus on the clinical evidence that supported their authorisation. Additionally, we evaluated the subsequent HTA decisions made in England by NICE for these EC therapies.

We’re looking forward to sharing the full results of our studies in November. To speak to us about these posters or any of our other research, speak to us at enquiries@maverex.com.